Merck & Co has inked another combination deal for its ultra-hot PD-1 inhibitor Keytruda (pembrolizumab); this time with Waltham, Mass.-based biotech Syndax Pharmaceuticals. The big pharma has placed significant emphasis on the success of Keytruda, which dominates the company's pipeline.
The pair announced the research collaboration on 31 March, but did not disclose financial details. The deal will combine the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?